A series of phenylvinyl derivatives of 4,6,6-trimethyl-2-oxo-1,2,5,6-tetrahydropyridine-3-carbonitriles has been synthesized and their cytotoxic activity towards HT-1080 (human fibrosarcoma) and MG 22A (mouse hepatoma) tumor cells studied. It was found that the 2-nitro-, 2- and 3-chloro, 2-fluoro, and 2-bromophenyl derivatives showed high cytotoxic activity towards both cell lines. The toxicity towards NIH 3T3 normal mouse embryonic fibroblasts depends on the nature and position of the substituent in the phenyl ring. The greatest selectivity of cytotoxic effect was seen in the 2-bromophenyl derivative.
Similar content being viewed by others
References
S. R. Klutchko, J. M. Hamby, D. H. Boschelli, Z. Wu, A. J. Kraker, A. M. Amar, B. G. Hartl, C. Shen, W. D. Klohs, R. W. Steinkampf, D. L. Driscoll, J. M. Nelson, W. L. Elliott, B. J. Roberts, C. L. Stoner, P. W. Vincent, D. J. Dykes, R. L. Panek, G. H. Lu, T. C. Major, T. K. Dahring, H. Hallak, L. A. Bradford, H. D. H. Showalter, and A. M. Doherty, J. Med. Chem., 41, 3276 (1998).
D. H. Boschelli, Z. Wu, S. R. Klutchko, H. D. H. Showalter, J. M. Hamby, G. H. Lu, T. C. Major, T. K. Dahring, B. Batley, R. L. Panek, J. Keiser, B. G. Hartl, A. J. Kraker, W. D. Klohs, B. J. Roberts, S. Patmore, W. L. Elliott, R. Steinkampf, L. A. Bradford, H. Hallak, and A. M. Doherty, J. Med. Chem., 41, 4365 (1998).
A. M. Thompson, G. W. Rewcastle, S. L. Boushelle, B. G. Hartl, A. J. Kraker, G. H. Lu, B. L. Batley, R. L. Panek, H. D. H. Showalter, and W. A. Denny, J. Med. Chem., 43, 3134 (2000).
A. J. Kraker, B. G. Hartl, A. M. Amar, M. R. Barvian, H. D. H. Showalter, and C. W. Moore, Biochem. Pharmacol., 60, 885 (2000).
A. Gazit, P. Yaish, C. Gilon, and A. Levitzki, J. Med. Chem., 32, 2344 (1989).
A. Gazit, N. Osherov, I. Posner, P. Yaish, E. Poradosu, C. Gilon, and A. Levitzki, J. Med. Chem., 34, 1896 (1991).
T. R. Burke, Drugs Fut., 17, 119 (1992).
V. G. Brunton, M. J. Lear, D. J. Robins, S. Williamson, and P. Workman, Anti-Cancer Drug Design, 9, 291 (1994).
M. Á. Ortega, M. J. Morancho, F. J. Martínez-Crespo, Y. Sainz, M. E. Montoya, A. L. Ceráin, and A. Monge, Eur. J. Med., 35, 21 (2000).
S. Sirikantaramas, T. Asano, H. Sudo, M. Yamazaki, and K. Saito, Curr. Pharm. Biotechnol., 8, 196 (2007).
S. O′Keilly and E. K. Rowinsky, Crit. Rev. Oncol. Hematol., 24, 47 (1996).
C. F. Verschraegen, Curr. Opin. Oncol. Endocr. Metab. Invest. Drugs, 1, 184 (1999).
K. Seiter, Expert Opin. Drug Safety, 4, 45 (2005).
J. A. Ajani, C. Takimoto, C. R. Becerra, A. Silva, L. Baez, A. Cohn, P. Major, M. Kamida, K. Feit, and R. De Jager, Invest. New Drugs, 23, 479 (2005).
C. H. Takimoto and R. Thomas, Ann. N. Y. Acad. Sci., 922, 224 (2000).
E. Lukevics and L. Ignatoviсh, in: M. Gielen and E. R. T. Tiekink (editors), Metallotherapeutic Drugs and Metal-based Diagnostic Agents, John Wiley and Sons Ltd., Chichester (2005), p. 83.
M. Muhsin, C. Gricks, and P. Kirkpatrick, Nature Rev. Drug Discov., 3, 825 (2004).
Wiley Handbook of Current and Emerging Drug Therapies, Vol. 1, John Wiley and Sons, Ltd., Hoboken, NJ, USA (2007), p. 478.
P. Norman, Curr. Opin. Invest. Drugs, 3, 313 (2002).
J. C. S. Bergh, T. H. Tötterman, B. C. Termander, K.A.-M.P. Strandgården., P. O. G. Gunnarsson, and B. I. Nilsson, Cancer Invest., 3, 204 (1997).
B. Hartley-Asap, J. Vukanovic, I. B.-J. K. Joseph, K. Strandgården, J. Polacek, and J. T. Isaacs, J. Urol., 158, 902 (1997).
A. J. Bridges, Emerging Drugs, 3, 279 (1998).
V. Nesterenko, K. S. Putt, and P. J. Hergenrother, J. Am. Chem. Soc., 125, 14672 (2003).
K. J. O′Byrne and W. P. Steward, Emerging Drugs, 6, 155 (2001).
J. A. Baur and D. A. Sinclair, Nature Rev. Drug Discov., 5, 493 (2006).
C. K. Osborne, N. Engl. J. Med., 339, 1609 (1998).
Wiley Handbook of Current and Emerging Drug Therapies, Vol. 1, John Wiley and Sons, Inc., Hoboken, NJ, USA ( 2007), pp. 250, 542.
S. Fortin, E. Moreau, J. Lacroix, J. C. Teulade, A. Patenaude, and R. C. Gaudreault, Bioorg. Med. Chem. Lett., 17, 2000 (2007).
D. J. Kerr, E. Hamel, M. K. Jung, and B. L. Flynn, Bioorg. Med. Chem., 15, 3290 (2007).
J. E. Robinson and R. J. K. Taylor, J. Chem. Soc., Chem. Commun., 16, 1617 (2007).
N. J. Lawrence, R. P. Patterson, Li-Ling Ooi, D. Cook, and S. Ducki, Bioorg. Med. Chem. Lett., 16, 5844 (2006).
F. Bellina, S. Cauteruccio, S. Monti, and R. Ross, Bioorg. Med. Chem. Lett., 16, 5757 (2006).
Guidance Document on Using in vitro Data to Estimate in vivo Starting Doses for Acute Toxicity, National Institute of Health, US Dept. of Health and Human Services (2001), p. 102; http://www.epa.gov/hpv/pubs/general/nih2001b.pdf
G. Veinberg, M. Vorona, I. Shestakova, I. Kanepe, O. Zharkova, R. Mezapuke, I. Turovskis, I. Kalvinsh, and E. Lukevics, Bioorg. Med. Chem., 8, 1033 (2000).
D. Jansone, M. Fleisher, G. Andreeva, L. Leite, and E. Lukevics, Khim. Geterotsikl. Soedin., 1863 (2005). [Chem. Heterocycl. Comp., 41, 1537 (2005)].
E. Lukevics, L. Ignatovich, I. Sleiksha, V. Muravenko, I. Shestakova, S. Belyakov, and J. Popelis, Appl. Organomet. Chem., 20, 454 (2006).
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Khimiya Geterotsiklicheskikh Soedinenii, No. 10, pp. 1529-1538, October, 2009.
Rights and permissions
About this article
Cite this article
Lukevics, E., Jansone, D., Leite, L. et al. Synthesis and cytotoxicity of phenyl-vinyl derivatives of 4,6,6-trimethyl-2-oxo-1,2,5,6-tetrahydropyridine-3-carbonitrile. Chem Heterocycl Comp 45, 1226–1234 (2009). https://doi.org/10.1007/s10593-010-0411-7
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10593-010-0411-7